Its covid-related partnership with BioNTech, a German vaccine developer ... A spiffy newish double-helix logo emphasises its devotion to science. The first topic of conversation is mergers ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $140.00.

Novavax (NVAX) announced preliminary results from the SHIELD-Utah study that showed Novavax’s COVID-19 Vaccine, Adjuvanted 2024-2025 Formula ...

Preliminary data showed Novavax's non-mRNA JN.1 COVID-19 vaccine induced lower frequency and severity of short-term side ...

BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to co-develop the prospect, BioNTech let the option expire as part of its ...

Backers, including BioNTech, have committed around one-third of the targeted IPO haul. China’s DualityBio filed to go public in Hong Kong last year but let that submission lapse. Having added ...

In this article, we are going to look at where BioNTech SE (NASDAQ:BNTX) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market conditions ...

BioNTech already owned part of InstaDeep as it backed the company's $100 million Series B last year, but will take 100% control of the company if the merger goes ahead as planned.

Companies like BioNTech, Moderna, and smaller players such as myNEO Therapeutics are at the forefront, using their expertise in mRNA technology, which was initially honed during the COVID-19 pandemic.

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

The firm grew demand, total head count, and its equity and nonequity partnership tiers, leading to a 27% surge in net income.

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new pandemic surged around them. By a year later, 66 million American adults had ...